BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2018;41:14-31. [PMID: 29263194 DOI: 10.2337/dci17-0057] [Cited by in Crossref: 258] [Cited by in F6Publishing: 220] [Article Influence: 64.5] [Reference Citation Analysis]
Number Citing Articles
1 Taouktsi N, Papageorgiou ST, Tousinas G, Papanikolopoulou S, Grammatikopoulou MG, Giannakoulas G, Goulis DG. Fragility of cardiovascular outcome trials (CVOTs) examining nutrition interventions among patients with diabetes mellitus: a systematic review of randomized controlled trials. Hormones (Athens) 2022. [PMID: 36129664 DOI: 10.1007/s42000-022-00396-5] [Reference Citation Analysis]
2 Abdel-Rahman N, Calderon-Margalit R, Cohen A, Elran E, Golan Cohen A, Krieger M, Paltiel O, Valinsky L, Ben-Yehuda A, Manor O. Longitudinal Adherence to Diabetes Quality Indicators and Cardiac Disease: A Nationwide Population-Based Historical Cohort Study of Patients With Pharmacologically Treated Diabetes. J Am Heart Assoc 2022;:e025603. [PMID: 36129044 DOI: 10.1161/JAHA.122.025603] [Reference Citation Analysis]
3 Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferović PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol 2022;21:144. [PMID: 35927730 DOI: 10.1186/s12933-022-01575-9] [Reference Citation Analysis]
4 Khera R, Schuemie MJ, Lu Y, Ostropolets A, Chen R, Hripcsak G, Ryan PB, Krumholz HM, Suchard MA. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 2022;12:e057977. [PMID: 35680274 DOI: 10.1136/bmjopen-2021-057977] [Reference Citation Analysis]
5 Galatou E, Mourelatou E, Hatziantoniou S, Vizirianakis IS. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022;11:1060. [DOI: 10.3390/antiox11061060] [Reference Citation Analysis]
6 Pradhan R, Patorno E, Azoulay L. Opportunities and challenges in implementing international multi-database pharmacoepidemiologic research. Am J Epidemiol 2022:kwac097. [PMID: 35597823 DOI: 10.1093/aje/kwac097] [Reference Citation Analysis]
7 Davey P, Alexandrou K, Farcaş AD. Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence. International Journal of Clinical Practice 2022;2022:1-13. [DOI: 10.1155/2022/2976811] [Reference Citation Analysis]
8 Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, Macdonald R, Hollenberg MD, Hill MA. Metformin: Is it a drug for all reasons and diseases? Metabolism 2022. [DOI: 10.1016/j.metabol.2022.155223] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mishriky BM, Cummings DM, Powell JR. Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Prim Care Diabetes 2022:S1751-9918(22)00073-0. [PMID: 35396200 DOI: 10.1016/j.pcd.2022.03.012] [Reference Citation Analysis]
10 Limonte CP, Hall YN, Trikudanathan S, Tuttle K, Hirsch IB, de Boer IH, Zelnick LR. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2022.108204] [Reference Citation Analysis]
11 Ghosal S, Sinha B. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis. Diabetes Res Clin Pract 2022;:109824. [PMID: 35271879 DOI: 10.1016/j.diabres.2022.109824] [Reference Citation Analysis]
12 Górriz JL, Romera I, Cobo A, O'Brien PD, Merino-Torres JF. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Ther 2022;13:389-421. [PMID: 35175551 DOI: 10.1007/s13300-021-01198-5] [Reference Citation Analysis]
13 Lin LA, Zhang Y, Straus W, Wang W. Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making. Ther Innov Regul Sci 2022. [PMID: 35138577 DOI: 10.1007/s43441-021-00349-x] [Reference Citation Analysis]
14 Pradhan R, Patorno E, Tesfaye H, Schneeweiss S, Yin H, Franklin J, Pawar A, Santella C, Yu OHY, Renoux C, Azoulay L. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol 2022:kwac021. [PMID: 35136902 DOI: 10.1093/aje/kwac021] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chatzis DG, Kolokathis K, Magounaki K, Chatzidakis S, Avramidis K, Leopoulou M, Angelopoulos TP, Doupis J. Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. touchREV Endocrinol 2021;17:92-101. [PMID: 35118454 DOI: 10.17925/EE.2021.17.2.92] [Reference Citation Analysis]
16 Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The prime type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ 2022;:1-32. [PMID: 35105267 DOI: 10.1080/13696998.2022.2035132] [Reference Citation Analysis]
17 Seidu S, Cos X, Brunton S, Harris S, Jansson S, Mata-cases M, Neijens A, Topsever P, Khunti K. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Luo J, Feldman R, Rothenberger S, Korytkowski M, Fischer MA, Gellad WF. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. J GEN INTERN MED. [DOI: 10.1007/s11606-021-07331-1] [Reference Citation Analysis]
19 He X. Glucose-dependent insulinotropic polypeptide and tissue inflammation: Implications for atherogenic cardiovascular disease. Eur J Inflamm 2022;20:205873922110704. [DOI: 10.1177/20587392211070402] [Reference Citation Analysis]
20 Tsai S, Lin M, Hsu C, Wu M, Wang I, Chen C. Trends of kidney transplantation from the 2020 annual report on kidney disease in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S144-74. [PMID: 34964815 DOI: 10.2337/dc22-S010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 30.0] [Reference Citation Analysis]
22 Sim R, Chong CW, Loganadan NK, Fong AYY, Navaravong L, Hussein Z, Khunti K, Lee SWH. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Diabet Med 2021;:e14780. [PMID: 34962662 DOI: 10.1111/dme.14780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lopez LN, Wang W, Loomba L, Afkarian M, Butani L. Diabetic kidney disease in children and adolescents: an update. Pediatr Nephrol 2021. [PMID: 34913986 DOI: 10.1007/s00467-021-05347-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Kim AH, Jang JE, Han J. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. Biomed Pharmacother 2022;145:112463. [PMID: 34839258 DOI: 10.1016/j.biopha.2021.112463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Lu T, Lee HC. Coronary Large Conductance Ca2+-Activated K+ Channel Dysfunction in Diabetes Mellitus. Front Physiol 2021;12:750618. [PMID: 34744789 DOI: 10.3389/fphys.2021.750618] [Reference Citation Analysis]
26 Abushamat LA, Reusch JEB. Evolving Concepts of Type 2 Diabetes Management. Med Clin North Am 2021;105:955-66. [PMID: 34688420 DOI: 10.1016/j.mcna.2021.06.003] [Reference Citation Analysis]
27 Kim JH, Butler AM, Ta CN, Sun Y, Maurer MS, Weng C. The potential role of EHR data in optimizing eligibility criteria definition for cardiovascular outcome trials. Int J Med Inform 2021;156:104587. [PMID: 34624661 DOI: 10.1016/j.ijmedinf.2021.104587] [Reference Citation Analysis]
28 Seetharaman R, Pawar S, Advani M. One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol 2021. [PMID: 34608666 DOI: 10.1111/bcp.15100] [Reference Citation Analysis]
29 Safouris A, Magoufis G, Tsivgoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert Opin Investig Drugs 2021;30:1025-35. [PMID: 34555978 DOI: 10.1080/13543784.2021.1985463] [Reference Citation Analysis]
30 Thethi TK, Bilal A, Pratley RE. Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectr 2021;34:217-24. [PMID: 34511847 DOI: 10.2337/ds20-0072] [Reference Citation Analysis]
31 Scheen AJ. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes Metab 2021;47:101275. [PMID: 34481962 DOI: 10.1016/j.diabet.2021.101275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Schroeder EB, Neugebauer R, Reynolds K, Schmittdiel JA, Loes L, Dyer W, Pimentel N, Desai JR, Vazquez-Benitez G, Ho PM, Anderson JP, O'Connor PJ. Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment. JAMA Netw Open 2021;4:e2126605. [PMID: 34559229 DOI: 10.1001/jamanetworkopen.2021.26605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Cruz P. Inpatient Hypoglycemia: The Challenge Remains. J Diabetes Sci Technol 2020;14:560-6. [PMID: 32389071 DOI: 10.1177/1932296820918540] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
34 Jacob S, Krentz AJ, Deanfield J, Rydén L. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs 2021;81:1373-9. [PMID: 34302636 DOI: 10.1007/s40265-021-01554-6] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Mittal N, Sehray V, Mittal R, Singh S. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. Eur J Pharmacol 2021;907:174320. [PMID: 34246651 DOI: 10.1016/j.ejphar.2021.174320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Gallego M, Zayas-Arrabal J, Alquiza A, Apellaniz B, Casis O. Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. Front Pharmacol 2021;12:687256. [PMID: 34305599 DOI: 10.3389/fphar.2021.687256] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Campbell DJT, Campbell DB, Ogundeji Y, Au F, Beall R, Ronksley PE, Quinn AE, Manns BJ, Hemmelgarn BR, Tonelli M, Spackman E. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs. Diabet Med 2021;38:e14622. [PMID: 34133781 DOI: 10.1111/dme.14622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zaccardi F, Davies MJ, Khunti K. The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future? Diabetes Obes Metab 2020;22 Suppl 3:21-34. [PMID: 32250528 DOI: 10.1111/dom.13929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
39 Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int 2021;99:314-8. [PMID: 33509353 DOI: 10.1016/j.kint.2020.08.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, Fahrbach K, Ustyugova A. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care 2021;9:e001313. [PMID: 33941549 DOI: 10.1136/bmjdrc-2020-001313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
41 García-Carro C, Vergara A, Bermejo S, Azancot MA, Sánchez-Fructuoso AI, Sánchez de la Nieta MD, Agraz I, Soler MJ. How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. J Clin Med 2021;10:2505. [PMID: 34198818 DOI: 10.3390/jcm10112505] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Younes AM, Mishriky BM, Powell JR, Cummings DM. The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials. Diabetes Res Clin Pract 2021;177:108878. [PMID: 34058302 DOI: 10.1016/j.diabres.2021.108878] [Reference Citation Analysis]
43 Geybels M, Wolthers BO, Kreiner FF, Rasmussen S, Bauer R. Surrogate endpoint evaluation using data from one large global randomized controlled trial. BMC Med Inform Decis Mak 2021;21:164. [PMID: 34016120 DOI: 10.1186/s12911-021-01516-8] [Reference Citation Analysis]
44 Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. J Am Heart Assoc 2021;10:e020237. [PMID: 34013739 DOI: 10.1161/JAHA.120.020237] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Romero A, Llauradó G, González-Clemente JM. Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type2 diabetes. Endocrinol Diabetes Nutr (Engl Ed) 2021:S2530-0164(21)00084-7. [PMID: 33965366 DOI: 10.1016/j.endinu.2020.12.004] [Reference Citation Analysis]
46 I Coleman C, S Costa O. Welcome to the cardiovascular outcomes trials issue. Future Cardiol 2021;17:399-402. [PMID: 33884891 DOI: 10.2217/fca-2021-0028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 MacIsaac RJ. Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiol 2021;17:459-73. [PMID: 33820430 DOI: 10.2217/fca-2020-0210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wood L, Bishop A, Lewis M, Smeets RJEM, Bronfort G, Hayden JA, Foster NE. Treatment targets of exercise for persistent non-specific low back pain: a consensus study. Physiotherapy 2021;112:78-86. [PMID: 34029781 DOI: 10.1016/j.physio.2021.03.005] [Reference Citation Analysis]
49 Shimazawa R, Ikeda M. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. Br J Clin Pharmacol 2021;87:3938-48. [PMID: 33704809 DOI: 10.1111/bcp.14814] [Reference Citation Analysis]
50 Schneeweiss S, Patorno E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr Rev 2021:bnab007. [PMID: 33710268 DOI: 10.1210/endrev/bnab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
51 Zhou YL, Zhang YG, Zhang R, Zhou YL, Li N, Wang MY, Tian HM, Li SY. Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital. Chin Med J (Engl) 2021;134:1317-23. [PMID: 33734138 DOI: 10.1097/CM9.0000000000001407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
52 Shanmugasundaram M, Pineda JRE, Murugapandian S. Glucose-Lowering Medications and Cardiovascular Outcomes. Curr Cardiol Rep 2021;23:24. [PMID: 33655453 DOI: 10.1007/s11886-021-01452-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Liu Y, Yu Z, Sun H. Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App. J Healthc Eng 2021;2021:6693810. [PMID: 33728034 DOI: 10.1155/2021/6693810] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Pradhan R, Abrahami D, Yin H, Yu OHY, Sahasrabudhe V, Baumfeld Andre E, Azoulay L. Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials. Clin Pharmacol Ther 2021;109:1219-23. [PMID: 33615445 DOI: 10.1002/cpt.2213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Tanaka A, Node K. Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 2021;20:41. [PMID: 33573675 DOI: 10.1186/s12933-021-01234-5] [Reference Citation Analysis]
56 Urquhart S, Willis S. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials. JAAPA 2020;33:19-30. [PMID: 32740122 DOI: 10.1097/01.JAA.0000669452.63883.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Hamedi Z, Mishriky BM, Okunrintemi V, Powell JR, Cummings DM. GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes Metab Res Rev 2021;37:e3436. [PMID: 33440044 DOI: 10.1002/dmrr.3436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
58 Monnier L, Colette C, Owens D. Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the "Gordian Knot"? Diabetes Metab 2021;47:101225. [PMID: 33454438 DOI: 10.1016/j.diabet.2021.101225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
59 Orsini Federici M, Gentilella R, Corcos A, Torre E, Genovese S. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care. Diabetes Metab Res Rev 2021. [PMID: 33900667 DOI: 10.1002/dmrr.3434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323. [PMID: 31497854 DOI: 10.1093/eurheartj/ehz486] [Cited by in Crossref: 925] [Cited by in F6Publishing: 1286] [Article Influence: 925.0] [Reference Citation Analysis]
61 Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. J Am Coll Cardiol 2020;75:1956-74. [PMID: 32327107 DOI: 10.1016/j.jacc.2020.02.056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
62 Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, Nolte J. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complications 2021;35:107813. [PMID: 33419634 DOI: 10.1016/j.jdiacomp.2020.107813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
63 Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J 2019;40:2907-19. [PMID: 30445605 DOI: 10.1093/eurheartj/ehy677] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
64 Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020;396:1745-57. [PMID: 33181081 DOI: 10.1016/S0140-6736(20)32234-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 73] [Article Influence: 19.0] [Reference Citation Analysis]
65 Su PF, Sie FC, Yang CT, Mau YL, Kuo S, Ou HT. Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysis. Environ Health 2020;19:110. [PMID: 33153466 DOI: 10.1186/s12940-020-00664-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Funck-brentano C. Indispensable but deceptive evidence-based medicine. Diabetes & Metabolism 2020;46:415-22. [DOI: 10.1016/j.diabet.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab 2021;23:276-80. [PMID: 33001548 DOI: 10.1111/dom.14211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
68 Munshi MN, Meneilly GS, Rodríguez-Mañas L, Close KL, Conlin PR, Cukierman-Yaffe T, Forbes A, Ganda OP, Kahn CR, Huang E, Laffel LM, Lee CG, Lee S, Nathan DM, Pandya N, Pratley R, Gabbay R, Sinclair AJ. Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol 2020;8:855-67. [PMID: 32946822 DOI: 10.1016/S2213-8587(20)30230-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
69 Coles B, Zaccardi F, Hvid C, Davies MJ, Khunti K. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years. Diabetes Obes Metab 2021;23:218-27. [PMID: 33026165 DOI: 10.1111/dom.14218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Nguyen C, Luthra R, Kuti E, Willey VJ. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both. Curr Med Res Opin 2020;36:1927-38. [PMID: 33023310 DOI: 10.1080/03007995.2020.1832455] [Reference Citation Analysis]
71 Weinrauch LA, Liu J, Segal AR, Woodward J, D'Elia JA. SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. J Diabetes Complications 2021;35:107761. [PMID: 33234402 DOI: 10.1016/j.jdiacomp.2020.107761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Prattichizzo F, La Sala L, Rydén L, Marx N, Ferrini M, Valensi P, Ceriello A. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol 2019;26:73-80. [PMID: 31766918 DOI: 10.1177/2047487319880040] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]
73 Katsanos AH, Hart RG. New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. JAMA Neurol 2020;77:1308. [DOI: 10.1001/jamaneurol.2020.2494] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
74 Kuss O, Hoyer A. A proportional risk model for time-to-event analysis in randomized controlled trials. Stat Methods Med Res 2021;30:411-24. [PMID: 32960748 DOI: 10.1177/0962280220953599] [Reference Citation Analysis]
75 Faulkenberg KD, Williams JB, Isaacs DM, West LM. Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure. Curr Treat Options Cardio Med 2020;22. [DOI: 10.1007/s11936-020-00825-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Khan MS, Fonarow GC, Mcguire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, Mcmurray JJ, Kosiborod MN, Butler J. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation 2020;142:1205-18. [DOI: 10.1161/circulationaha.120.045888] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
77 Freudenberg DL, Covington LP, Young RB, Lopez ND, Patel MV, MacLaughlin EJ. Impact of a Pharmacist-Driven Protocol to Improve Guideline-Concordant Prescribing of Diabetes Medications in Patients With Atherosclerotic Cardiovascular Disease: A Pilot Study. J Pharm Pract 2022;35:80-5. [PMID: 32938319 DOI: 10.1177/0897190020958245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. J Clin Pharm Ther 2020;45 Suppl 1:61-72. [PMID: 32910492 DOI: 10.1111/jcpt.13226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Xie Y, Bowe B, Gibson AK, McGill JB, Yan Y, Maddukuri G, Al-Aly Z. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care 2020;43:2785-95. [PMID: 32912850 DOI: 10.2337/dc20-1231] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
80 Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf 2020;19:1095-104. [PMID: 32750250 DOI: 10.1080/14740338.2020.1806234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
81 Wilding JPH, Jacob S. Cardiovascular outcome trials in obesity: A review. Obes Rev 2021;22:e13112. [PMID: 32893459 DOI: 10.1111/obr.13112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
82 Neuen BL, Jardine MJ, Perkovic V. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant 2020;35:i48-55. [PMID: 32003833 DOI: 10.1093/ndt/gfz252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
83 Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care 2019;7:e000742. [PMID: 32043472 DOI: 10.1136/bmjdrc-2019-000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
84 Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-77. [PMID: 32855502 DOI: 10.1038/s41574-020-0392-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 40.0] [Reference Citation Analysis]
85 Melzer Cohen C, Hallén N, Chodick G, Bourvine L, Waner T, Karasik A. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel. Value Health Reg Issues 2020;22:83-92. [PMID: 32798839 DOI: 10.1016/j.vhri.2020.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Si L, Willis MS, Asseburg C, Nilsson A, Tew M, Clarke PM, Lamotte M, Ramos M, Shao H, Shi L, Zhang P, McEwan P, Ye W, Herman WH, Kuo S, Isaman DJ, Schramm W, Sailer F, Brennan A, Pollard D, Smolen HJ, Leal J, Gray A, Patel R, Feenstra T, Palmer AJ. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value Health 2020;23:1163-70. [PMID: 32940234 DOI: 10.1016/j.jval.2020.04.1832] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
87 Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy 2019;17:615-27. [PMID: 31264138 DOI: 10.1007/s40258-019-00494-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Shubrook JH, Pak J, Dailey G. Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey. Adv Ther 2020;37:3630-9. [PMID: 32621271 DOI: 10.1007/s12325-020-01405-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
89 Ilias I, Thomopoulos C, Michalopoulou H, Bazoukis G, Tsioufis C, Makris T. Antidiabetic drugs and blood pressure changes.Pharmacol Res. 2020;161:105108. [PMID: 32738493 DOI: 10.1016/j.phrs.2020.105108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
90 Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. Diabetes Ther 2020;11:2041-55. [PMID: 32700188 DOI: 10.1007/s13300-020-00883-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
91 Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S; On behalf of RSSDI-ESI Consensus Group. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Int J Diabetes Dev Ctries 2020;40:1-122. [DOI: 10.1007/s13410-020-00819-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
92 Thomopoulos C, Bazoukis G, Ilias I, Tsioufis C, Makris T. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials. J Hypertens 2019;37:1939-49. [PMID: 31157748 DOI: 10.1097/HJH.0000000000002152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Bosun-Arije FS, Ling J, Graham Y, Hayes C. Organisational factors influencing non-pharmacological management of type 2 diabetes mellitus (T2DM) in public hospitals across Lagos, Nigeria: A qualitative study of nurses' perspectives. Diabetes Res Clin Pract 2020;166:108288. [PMID: 32615277 DOI: 10.1016/j.diabres.2020.108288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Biessels GJ. A first lead in dementia prevention in people with diabetes. The Lancet Neurology 2020;19:559-60. [DOI: 10.1016/s1474-4422(20)30174-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Farjo PD, Barghouthi N, Chima N, Desai A, Fang W, Giordano J, Bianco CM. Use of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment. Am J Cardiol 2020;125:1829-35. [PMID: 32305226 DOI: 10.1016/j.amjcard.2020.03.027] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Yang CT, Yang CY, Ou HT, Kuo S. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol 2020;19:83. [PMID: 32534570 DOI: 10.1186/s12933-020-01053-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
97 Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Prim Care Diabetes 2021;15:31-51. [PMID: 32532635 DOI: 10.1016/j.pcd.2020.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
98 Vecchié A, Montecucco F, Carbone F, Dallegri F, Bonaventura A. Diabetes and Vascular Disease: Is It All About Glycemia? Curr Pharm Des 2019;25:3112-27. [PMID: 31470783 DOI: 10.2174/1381612825666190830181944] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
99 Neuen BL, Cherney DZ, Jardine MJ, Perkovic V. Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. CMAJ 2019;191:E1128-35. [PMID: 31615819 DOI: 10.1503/cmaj.190047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
100 Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res 2020;126:1501-25. [PMID: 32437308 DOI: 10.1161/CIRCRESAHA.120.315913] [Cited by in Crossref: 45] [Cited by in F6Publishing: 99] [Article Influence: 22.5] [Reference Citation Analysis]
101 Kalra S, Ghosh S, Das AK, Nair T, Bajaj S, Priya G, Mehrotra RN, Das S, Shah P, Deshmukh V, Chawla M, Sanyal D, Chandrasekaran S, Khandelwal D, Joshi A, Eliana F, Permana H, Fariduddin MD, Shrestha PK, Shrestha D, Kahandawa S, Sumanathilaka M, Shaheed A, Rahim AA, Orabi A, Al-Ani A, Hussein W, Kumar D, Shaikh K. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel. Indian Heart J 2020;72:7-13. [PMID: 32423565 DOI: 10.1016/j.ihj.2020.01.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Mishriky BM, Okunrintemi V, Jain S, Sewell KA, Powell JR, Cummings DM. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis. Diabetes Metab 2021;47:101160. [PMID: 32439471 DOI: 10.1016/j.diabet.2020.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
103 Uhrig JL, Page SO, Mishriky BM, Patil SP, Powell JR, Sewell K, Mian MR, Cummings DM. Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review. J Clin Pharmacol 2020;60:980-91. [PMID: 32396236 DOI: 10.1002/jcph.1599] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Chin KL, Hidayat FM, Ofori-Asenso R, Ilomäki J, Bell JS, Zoungas S, Liew D. Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data. Drugs Aging 2020;37:393-8. [PMID: 32227290 DOI: 10.1007/s40266-020-00759-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Jayakumari C, Jabbar PK, Soumya S, Jayakumar RV, Das DV, Girivishnu G, Gopi A, Gomez R, Sreenath R, Nair A. Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction. Diabetes Spectr 2020;33:299-306. [PMID: 33223767 DOI: 10.2337/ds19-0046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne) 2020;11:178. [PMID: 32308645 DOI: 10.3389/fendo.2020.00178] [Cited by in Crossref: 21] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
107 Górriz JL, Soler MJ, Navarro-González JF, García-Carro C, Puchades MJ, D'Marco L, Martínez Castelao A, Fernández-Fernández B, Ortiz A, Górriz-Zambrano C, Navarro-Pérez J, Gorgojo-Martinez JJ. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med 2020;9:E947. [PMID: 32235471 DOI: 10.3390/jcm9040947] [Cited by in Crossref: 14] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
108 Verdecchia P, Angeli F, Cavallini C, Aita A, Turturiello D, Reboldi G. The revolution of the anti-diabetic drugs in cardiology. Eur Heart J Suppl 2020;22:E162-6. [PMID: 32523463 DOI: 10.1093/eurheartj/suaa084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Koufakis T, Dimitriadis G, Kotsa K. A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas? J Diabetes 2020;12:499-502. [PMID: 32202061 DOI: 10.1111/1753-0407.13035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Hinton W, Feher M, Munro N, Joy M, de Lusignan S. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care. Diabet Med 2020;37:1499-508. [PMID: 32128875 DOI: 10.1111/dme.14290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
111 Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol 2020;15:465-73. [PMID: 32132141 DOI: 10.2215/CJN.11881019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
112 Lee CL, Chen CH, Wu MJ, Tsai SF. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Ther Adv Chronic Dis 2020;11:2040622319898370. [PMID: 32166009 DOI: 10.1177/2040622319898370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
113 Schernthaner G, Groop PH, Kalra PA, Ronco C, Taal MW. Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes Obes Metab 2020;22:1024-34. [PMID: 32037647 DOI: 10.1111/dom.13994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, He Z, Zhao W, Chen C, Qiu K, Wu J. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. The Lancet Diabetes & Endocrinology 2020;8:192-205. [DOI: 10.1016/s2213-8587(19)30422-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
115 Whiteley WN, Anand S, Bangdiwala SI, Bosch J, Canavan M, Chertkow H, Gerstein HC, Gorelick P, O'Donnell M, Paré G, Pigeyre M, Seshadri S, Sharma M, Smith EE, Williamson J, Cukierman-Yaffe T, Hart RG, Yusuf S. Are large simple trials for dementia prevention possible? Age Ageing 2020;49:154-60. [PMID: 31830268 DOI: 10.1093/ageing/afz152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
116 Cos X, Seidu S, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. Impact on guidelines: The general practitioner point of view. Diabetes Res Clin Pract 2020;166:108091. [PMID: 32105769 DOI: 10.1016/j.diabres.2020.108091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 2019;34:208-30. [PMID: 30753708 DOI: 10.1093/ndt/gfy407] [Cited by in Crossref: 78] [Cited by in F6Publishing: 92] [Article Influence: 39.0] [Reference Citation Analysis]
118 Ghosal S, Sinha B. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials. Curr Diabetes Rev 2020;16:917-21. [PMID: 32026781 DOI: 10.2174/1573399816666200206113549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:l7078. [PMID: 32024657 DOI: 10.1136/bmj.l7078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
120 Snaith JR, Holmes-walker DJ, Greenfield JR. Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies? Trends in Endocrinology & Metabolism 2020;31:150-64. [DOI: 10.1016/j.tem.2019.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
121 Low Wang CC, Everett BM, Burman KD, Wilson PWF. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? Circulation 2019;139:1741-3. [PMID: 30933621 DOI: 10.1161/CIRCULATIONAHA.118.038771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
122 Bellary S, Tahrani AA, Barnett AH. Evidence-based prescribing of diabetes medications: are we getting closer? Lancet Diabetes Endocrinol 2020;8:176-7. [PMID: 32006520 DOI: 10.1016/S2213-8587(20)30020-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation 2020;141:843-62. [PMID: 31992065 DOI: 10.1161/CIRCULATIONAHA.119.041022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
124 Quattrocchi E, Goldberg T, Marzella N. Management of type 2 diabetes: consensus of diabetes organizations. Drugs Context 2020;9:212607. [PMID: 32158490 DOI: 10.7573/dic.212607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
125 Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, Kotsa K. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Ther 2020;45:883-91. [PMID: 31905245 DOI: 10.1111/jcpt.13107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
126 Neugebauer R, Schroeder EB, Reynolds K, Schmittdiel JA, Loes L, Dyer W, Desai JR, Vazquez-Benitez G, Ho PM, Anderson JP, Pimentel N, O'Connor PJ. Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins. JAMA Netw Open 2020;3:e1918554. [PMID: 31977057 DOI: 10.1001/jamanetworkopen.2019.18554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
127 Monteiro P, Aguiar C, Matos P, Silva-Nunes J, Birne R, Branco P, Calado J, Melo M, Polónia J. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. Rev Port Cardiol (Engl Ed) 2019;38:721-35. [PMID: 31892455 DOI: 10.1016/j.repc.2019.02.008] [Reference Citation Analysis]
128 Žunić T, Ponjavić M. The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection. Arhiv za farmaciju 2020;70:198-223. [DOI: 10.5937/arhfarm2004198q] [Reference Citation Analysis]
129 Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH. Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. J Obes Metab Syndr 2019;28:254-61. [PMID: 31909368 DOI: 10.7570/jomes.2019.28.4.254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
130 Riddle MC. Diabetes Care in 2020: Following and Leading the Stories of Diabetes. Diabetes Care 2020;43:3-4. [PMID: 31862819 DOI: 10.2337/dci19-0065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Nassif ME, Kosiborod M. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol 2019;124 Suppl 1:S12-9. [PMID: 31741435 DOI: 10.1016/j.amjcard.2019.10.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
132 Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS;  American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56-e528. [PMID: 30700139 DOI: 10.1161/cir.0000000000000659] [Cited by in Crossref: 2988] [Cited by in F6Publishing: 3631] [Article Influence: 996.0] [Reference Citation Analysis]
133 Giorgino F, Caruso I, Moellmann J, Lehrke M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 2020;104:154045. [PMID: 31821814 DOI: 10.1016/j.metabol.2019.154045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
134 Jürgens M, Schou M, Hasbak P, Kjær A, Wolsk E, Zerahn B, Wiberg M, Brandt NH, Gæde PH, Rossing P, Faber J, Inzucchi S, Gustafsson F, Kistorp CM. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open 2019;9:e029098. [PMID: 31780586 DOI: 10.1136/bmjopen-2019-029098] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Patorno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz AJ, Bessette LG, Kulldorff M, Schneeweiss S. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab 2020;3:e00103. [PMID: 31922030 DOI: 10.1002/edm2.103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
136 Luo J, Dancel E, Bains S, Fanikos P, Fischer MA. Academic Detailing in the New Era of Diabetes Medication Management. Curr Diab Rep 2019;19:140. [PMID: 31754838 DOI: 10.1007/s11892-019-1252-0] [Reference Citation Analysis]
137 Shimazawa R, Ikeda M. Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes. J Pharm Policy Pract 2019;12:30. [PMID: 31832207 DOI: 10.1186/s40545-019-0193-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
138 Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ 2019;367:l5887. [PMID: 31690574 DOI: 10.1136/bmj.l5887] [Cited by in Crossref: 28] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
139 Cattadori G, Pantanetti P, Ambrosio G. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Research and Clinical Practice 2019;157:107835. [DOI: 10.1016/j.diabres.2019.107835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
140 Eckel RH, Farooki A, Henry RR, Koch GG, Leiter LA. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? Clin Diabetes 2019;37:316-37. [PMID: 31660005 DOI: 10.2337/cd19-0001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
141 Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, Pratley RE, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR; DEVOTE Study Group. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Ther 2020;11:53-70. [PMID: 31667706 DOI: 10.1007/s13300-019-00715-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
142 Petrie JR. Cardiovascular disease in type 1 diabetes: the elephant in the clinic. Cardiovasc Endocrinol Metab 2019;8:1-2. [PMID: 31646293 DOI: 10.1097/XCE.0000000000000170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Monteiro P, Aguiar C, Matos P, Silva-nunes J, Birne R, Branco P, Calado J, Melo M, Polónia J. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. Revista Portuguesa de Cardiologia (English Edition) 2019;38:721-35. [DOI: 10.1016/j.repce.2019.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Guardado-mendoza R, Cázares-sánchez D, Evia-viscarra ML, Jiménez-ceja LM, Durán-pérez EG, Aguilar-garcía A. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study. Diabetes Research and Clinical Practice 2019;156:107864. [DOI: 10.1016/j.diabres.2019.107864] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr 2019;11:80. [PMID: 31572499 DOI: 10.1186/s13098-019-0476-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
146 McCoy RG, Rodriguez-Gutierrez R. Measuring the Quality of Diabetes Care-Reply. JAMA 2019;322:1212-3. [PMID: 31550025 DOI: 10.1001/jama.2019.11148] [Reference Citation Analysis]
147 Wexler DJ. Sulfonylureas and Cardiovascular Safety: The Final Verdict? JAMA 2019;322:1147-9. [PMID: 31536110 DOI: 10.1001/jama.2019.14533] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
148 Wojcik C, Warden BA. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Curr Cardiol Rep 2019;21:130. [PMID: 31522263 DOI: 10.1007/s11886-019-1219-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
149 Willis M, Asseburg C, Nilsson A, Neslusan C. Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. Diabetes Ther 2019;10:1753-69. [PMID: 31446570 DOI: 10.1007/s13300-019-00681-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Varin EM, McLean BA, Lovshin JA. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. Can J Diabetes 2020;44:68-77. [PMID: 31699625 DOI: 10.1016/j.jcjd.2019.08.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
151 Herder M. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency. Milbank Q 2019;97:820-57. [PMID: 31407412 DOI: 10.1111/1468-0009.12413] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
152 Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461:104-126. [PMID: 31392745 DOI: 10.1111/nyas.14211] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
153 Wexler DJ, Krause-Steinrauf H, Crandall JP, Florez HJ, Hox SH, Kuhn A, Sood A, Underkofler C, Aroda VR; GRADE Research Group. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2019;42:2098-107. [PMID: 31391203 DOI: 10.2337/dc19-0901] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
154 Górriz JL, Cos Claramunt FX, Duque N, Matali A. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. Prim Care Diabetes 2019;13:485-94. [PMID: 31400992 DOI: 10.1016/j.pcd.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Bailey CJ, Day C. The future of new drugs for diabetes management. Diabetes Res Clin Pract 2019;155:107785. [PMID: 31326453 DOI: 10.1016/j.diabres.2019.107785] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
156 Ikeda M, Shimazawa R. Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. J Gen Fam Med 2019;20:129-38. [PMID: 31312579 DOI: 10.1002/jgf2.244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 Deed G, Atherton JJ, d'Emden M, Rasalam R, Sharma A, Sindone A. Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice? Diabetes Ther 2019;10:1625-43. [PMID: 31292928 DOI: 10.1007/s13300-019-0663-x] [Reference Citation Analysis]
158 Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, Fernando K, James J, Milne N, Viljoen A, Wilding J; As part of The Improving Diabetes Steering Committee. SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. Diabetes Ther 2019;10:1595-622. [PMID: 31290126 DOI: 10.1007/s13300-019-0657-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
159 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-kurktschiev T, Abella M, Alebuena A, Almagro S, Amoroso E, Anadon P, Andreu E, Aristimuño G, Arzadun M, Barbieri M, Barcudi R, Bartolacci I, Bolobanich G, Bordonava A, Bustamante Labarta M, Bustos B, Caccavo A, Camino A, Cantero M, Carignano M, Cartasegna L, Cipullo M, Commendatore V, Conosciuto V, Costamagna O, Crespo C, Cuello J, Cuneo C, Cusimano S, Dean S, Dituro C, Dominguez A, Farah M, Fernandez A, Fernandez F, Ferrari A, Flammia P, Fuentealba J, Gallardo KB, Garcia C, Garcia Duran R, Garrido M, Gavicola R, Gerbaudo C, Gilli G, Giotto AP, Godoy Bolzán P, Gomez Vilamajo O, Guerlloy F, Guridi C, Gutierrez Garrido N, Hasbani E, Hermida S, Hominal M, Hrabar A, Ingaramo A, Izzicupo A, Krynski M, Lagrutta M, Lanchiotti P, Langhe M, Leonard V, Llanos J, Lopez Santi R, Lowenstein J, Luquez C, Mackinnon I, Mana M, Manzur S, Marino J, Martella C, Martinez R, Matias R, Matkovich J, Meritano M, Montaña O, Mulazzi M, Ochoa J, Paterlini G, Pelagagge M, Peralta Lopez ME, Prado A, Pruyas L, Racca M, Ricotti C, Rodriguez C, Romero Vidomlansky M, Ronderos R, Sadowski AL, Sala J, Sánchez A, Santoro A, Schiavi L, Sein M, Sernia V, Serra L, Sicer M, Smith T, Soso L, Sposetti G, Steinacher A, Stival J, Tedesco J, Tonin H, Tortolo M, Ulla M, Vallejos J, Vico M, Virgillito L, Visco V, Vogel D, Waisman F, Zaidman C, Zucchiatti N, Badshah I, Cohen N, Colman P, Colquhoun D, Davis T, Fourlanos S, Fulcher G, Hamlyn J, Haywood C, Hocking S, Huchinson M, Jeffries W, Kyl M, Lo C, Mah P, Makepeace A, Marope D, Nanayakkar N, Nankervis A, Palmer N, Palolus B, Pillai S, Price S, Price S, Proietto J, Reutens A, Rodrigo N, Sheikh A, Smith G, So M, Soldatos G, Stuckey B, Sumithran P, Teede H, Vora P, Williams L, Abib E, Adão Poço C, Alves ÉF, Andreatta Bernardi Barea J, Avezum Oliveira L, Castro DLDCD, Correa da Cruz I, Costa M, Cruz I, Cunha S, Da Silva MAV, de Carvalho Camara Bona R, de Paula B, Eliaschewitz F, Fazolli G, Ferreira Filho CA, Fortes J, França C, Franco DR, Genestreti PR, Giorgeto F, Gonçalves RM, Grossman ME, Henrique Marcelino AC, Hernandes M, Horta A, Jaeger C, Kaneblai M, Kauffman Rutenberg C, Kerr Saraiva JF, Lemos MA, Maia L, Manenti ER, Marques M, Melissa Valerio C, Moreira R, Mothé F, Mouco OM, Moura P, Moura Jorge JC, Nakashima C, Nakazone M, Napoli T, Nunes C, Nunes Salles JE, Oliveira K, Oliveira M, Pantano GDS, Petri F, Piazza L, Pires AC, Pizzato P, Prata S, Precoma D, Rech R, Reis G, Reis H, Resende E, Ribas Fortes J, Rodovalho S, Rossi dos Santos F, Salles JE, Sampaio CR, Santos T, Santos dos Santos V, Silva e Quadros T, Silveira D, Siqueira KN, Teireira M, Uehara M, Valerio C, Vianna H, Vidotti MH, Visconti GDL, Zanella MT, Andreeva V, Borisov R, Botushanov N, Dimitrov G, Dimova K, Dragoychev T, Grigorova V, Gushterova V, Ivanov I, Kocelova T, Kurktschiev D, Miletieva M, Nenkova-gugusheva N, Pancheva R, Pavlova M, Raev D, Spasova V, Stoikov A, Troev D, Yanev T, Yoncheva-mihaylova M, Abitbol A, Ajala B, Alguwaihes A, Ardilouze J, Aris-jilwan N, Arnaout A, Aronson R, Aslam N, Babin S, Bailargeon J, Bailey A, Bajaj H, Beauchesne C, Beca S, Belanger A, Bell A, Bellabarba D, Berard L, Berenbaum B, Bergeron V, Berlingieri J, Bernier F, Bishara P, Blank D, Blumer I, Brault S, Breton D, Carpentier A, Cha J, Chandra P, Chiasson J, Conway JR, Couture G, Couture N, Dagenais G, Datta D, D'ignazio G, Dumas R, Fay D, Frechette A, Frenette L, Fung D, Gagnon N, Galter M, Garon J, Gauthier JS, Geadah C, Gilbert J, Girard R, Goldenberg R, Grossman LD, Gupta N, Halle J, Hivert M, Houde G, Houlden R, Hramiak I, Jablonski T, Jain AJ, Khandwala H, Khosla M, Lachance C, Laflamme E, Langlois M, Larivee L, Liutkus J, Lochnan H, Malik S, Mcdonald C, Mehta P, Mihailidis J, Milot A, Narula P, Nault P, Nayar A, Nisker W, Ouellet G, Palardy J, Patel M, Paul T, Pedersen S, Perron P, Pesant M, Poirier P, Poulin M, Punthakee Z, Rehman W, Ross S, Sagar P, Saliba N, Sandler S, Schiffrin A, Schlosser R, Seth-sharma A, Sherman M, Sionit D, Sivakumar T, Soto J, St-amour E, Steen O, Sussman J, Telner A, Tobe S, Twum-barima D, Van Zanten A, Vanrossum N, Vecchiarelli J, Ward R, Wessengel J, Weisnagel S, Wilderman I, Woo V, Yakubovich N, Yale J, Yared Z, Acevedo M, Aguirre ML, Aizman A, Barroso MS, Cobos L, Danin Vargas A, Descalzi B, Godoy G, Grumberg E, Lahsen R, Larenas G, Ortiz E, Paredes J, Potthoff S, Retamal E, Rojas L, Salgado M, Santibanez C, Solis C, Stokins B, Accini J, Acebedo J, Agudelo Baena LM, Alarcon S, Angel J, Arcos E, Aroca Martinez M, Atuesta L, Balaguera J, Ballestas D, Barrera SI, Barrios Reyes R, Bayona A, Bermudez A, Bernal DZ, Blanquicett M, Bravo V, Bueno W, Burbano Delgado A, Cadena A, Cadena A, Caicedo S, Celemin C, Consuegra R, Contreras Pimienta C, Corredor KJ, Cure C, De La Hoz Rueda LD, Delgado E, Diaz S, Diego M, Donado A, Encinales Sanabria W, Escobar J, Escorcia G, Forero L, Fuentes L, Garcia M, Garcia Lozada H, Garcia Ortiz L, Giraldo A, Gomez Gonzalez L, Granada J, Gutierrez C, Henao N, Hernandez E, Herrera Uejbe OM, Higuera Cobos JD, Ibarra Gómez J, Jaimes EH, Jaramillo M, Jaramillo N, Jaramillo Gomez C, Jaramillo Sanchez M, Jarava Durán I, Lopez Ceballos C, Madrid C, María Amastha E, Mercado J, Molina DI, Molina Soto J, Montoya C, Morales A, Muñoz C, Orozco LA, Osorio O, Palmera Sanchez JM, Peña A, Perez J, Perez Agudelo J, Pérez Amador G, Pertuz C, Posada I, Puerta C, Quintero A, Quiroz D, Rendon C, Reyes A, Reyes A, Ripoll D, Rivera C, Rocha M, Rodriguez JF, Rodriguez Villanueva KA, Rodriguez Zabala JE, Rojas S, Romero M, Rosero R, Rosillo Cardenas AR, Rueda L, Sanchez G, Sanchez T, Sotomayor Herazo A, Suarez M, Torres M, Trujillo F, Urina M, Van Strahlen L, Velandia C, Velasquez Guzman C, Velazquez E, Vidal Prada T, Yepez Alvaran JP, Zarate D, Andelova J, Benesova R, Buzova B, Cech V, Chodova I, Choura M, Dufka A, Gamova A, Gorgol J, Hala T, Havlova H, Hlavkova D, Horanska P, Ilcisin-valova J, Jenickova P, Jerabek O, Kantorova I, Kolomaznikova K, Kopeckova I, Kopeckova M, Linhart K, Linhart T, Malecha J, Malicherova E, Neubauerova D, Oznerova M, Partys R, Pederzoliova E, Petrusova M, Prymkova V, Racicka E, Reissova I, Roderova E, Stanek L, Striova A, Svarcova D, Svoboda P, Szeghy Malicharova E, Urge J, Vesely L, Wasserburger B, Wasserburgerova H, Zahumensky E, Zamrazil V, Alawi H, Anastasiadis E, Axthelm E, Bieler T, Buhrig C, Degtyareva E, Dellanna F, Derwahl K, Diessel S, Dogiami B, Dorn-weitzel K, Ernst M, Faulmann G, Fetscher B, Forst T, Freyer-lahres G, Funke K, Ganz X, Gleixner C, Hanefeld C, Heinrichs S, Helleberg S, Henkel E, Hetzel GR, Hoffmann C, Jacob F, Jacob S, John F, Jonczyk A, Kamke W, Klein C, Kleinhardt M, Kleophas W, Kosch C, Kreutzmann K, Kühn A, Lee-barkey YH, Lier A, Maatouk S, Minnich J, Mitry M, Muessig I, Nicula D, Niemann M, Nothroff J, Ott P, Pfuetzner A, Pfützner A, Pistrosch F, Pohl W, Prochazkova Z, Retkowska M, Rosin H, Sachsenheimer D, Samer H, Sanuri M, Schaefer A, Schaper F, Schulze E, Schulze M, Schumann M, Segiet T, Sowa V, Stahl H, Steinfeldt F, Teige M, Trieb B, Tschoepe D, Uebel P, Warken B, Weigmann I, Weyland K, Wilhelm K, Balo T, Balsay M, Bende I, Bezzegh K, Birkus Z, Buday B, Csomai M, Deak L, Dezso E, Faludi P, Faluvegi M, Fazekas I, Feher A, Fejer C, Finta E, Fulcz A, Gaal Z, Gurzo M, Hati K, Herczeg G, Jozsef I, Juhasz M, Keltai K, Koranyi L, Kulcsar E, Kun K, Laczko A, Literáti-nagy B, Mezo I, Mileder M, Moricz I, Nagy K, Nagybaczoni B, Nemeth C, Oze A, Pauer J, Peterfai E, Polocsanyi B, Poor F, Reiber I, Salamon C, Sebestyen J, Torok I, Tuu M, Varga A, Vass V, Ahn CM, Ahn C, Byungwon P, Chang H, Chang K, Choi E, Choi HS, Chung J, Hong BK, Hong YJ, Hyon MS, Jeong MH, Kang S, Kim B, Kim J, Kim JH, Kim K, Kim K, Kim MH, Kim P, Kim S, Kim Y, Kim YK, Koh YS, Kwon HM, Lee BK, Lee B, Lee JB, Lee M, Lim Y, Min PK, Park JS, Park J, Park KH, Park S, Pyun WB, Rim SJ, Ryu D, Seo H, Seung KB, Shin D, Sim DS, Yoon YW, Andersone I, Babicka K, Balcere I, Barons R, Capkovska I, Geldnere K, Grigane I, Jegere B, Lagzdina I, Mora L, Pastare S, Ritenberga R, Romanova J, Saknite I, Sidlovska N, Sokolova J, Steina S, Strizko I, Teterovska D, Vizina B, Barsiene L, Belozariene G, Daugintyte-petrusiene L, Drungiliene N, Garsviene N, Grigiene A, Grizas V, Jociene V, Kalvaitiene D, Kaupiene J, Kavaliauskiene J, Kozloviene D, Lapteva I, Maneikiene B, Marcinkeviciene J, Markauskiene V, Meiluniene S, Norkus A, Norviliene R, Petrenko V, Radzeviciene R, Sakalyte G, Urbonas G, Urbutiene S, Vasiliauskas D, Velickiene D, Aguilar C, Alcocer M, Avalos-ramirez JA, Banda-elizondo R, Bricio-ramirez R, Cardenas Mejia K, Cavazos F, Chapa J, Cienfuegos E, De la Peña A, de la Peña Topete G, De los Rios Ibarra MO, Elias D, Flores-moreno C, Garcia Hernandez P, Gonzalez LG, Guerra Moya RL, Guerra-lopez A, Hernandez Baylon R, Herrera Colorado C, Herrera-marmolejo M, Islas-palacios N, Lopez E, Lopez F, Lopez Alvarado A, Luna Ceballos RI, Morales Villegas E, Moreno-virgen G, Parra Perez RL, Pascoe Gonzalez S, Peralta-cantu I, Previn R, Ramirez R, Ramirez R, Ramos Zavala MG, Rodriguez M, Salgado-sedano R, Sanchez-aguilar AC, Santa Rosa Franco E, Sauque-reyna L, Suarez Otero R, Torres I, Velarde-harnandez E, Villagordoa J, Villeda-espinoza E, Vital-lopez J, Zavala- Bello CJ, Baker J, Barrington-ward E, Brownless T, Carroll R, Carson S, Choe M, Corin A, Corley B, Cutfield R, Dalaman N, Dixon P, Drury P, Dyson K, Florkowski C, Ford M, Frengley W, Helm C, Katzen C, Kerr J, Khanolkar M, Kim D, Koops R, Krebs J, Leikis R, Low K, Luckey A, Luke R, Macaulay S, Marks R, Mcnamara C, Millar-coote D, Miller S, Mottershead N, Reid J, Robertson N, Rosen I, Rowe D, Schmiedel O, Scott R, Sebastian J, Sheahan D, Stiebel V, Ternouth I, Tofield C, Venter D, Williams M, Williams M, Wu F, Young S, Arciszewska M, Bochenek A, Borkowski P, Borowy P, Chrzanowski T, Czerwinski E, Dwojak M, Grodzicka A, Janiec I, Jaruga J, Jazwinska-tarnawska EK, Jedynasty K, Juzwiak-czapiewska D, Karczewicz-janowska J, Konieczny J, Konieczny M, Korol M, Kozina M, Krzyzagorska E, Kucharczyk-petryka E, Laz R, Majchrzak A, Mrozowska Z, Mularczyk M, Nowacka E, Peczynska J, Petryka R, Pietrzak R, Pisarczyk-wiza D, Rozanska A, Ruzga Z, Rzeszotarska E, Sacha M, Sekulska M, Sidorowicz-bialynicka A, Stasinska T, Strzelecka-sosik A, Swierszcz T, Szymkowiak KM, Turowska O, Wisniewska K, Wiza M, Wozniak I, Zelazowska K, Ziolkowska-gawron B, Zytkiewicz-jaruga D, Albota A, Alexandru C, Avram R, Bala C, Barbonta D, Barbu R, Braicu D, Calutiu N, Catrinoiu D, Cerghizan A, Ciorba A, Craciun A, Doros R, Duma L, Dumitrache A, Ferariu I, Ferician Moza A, Ghergan A, Ghise G, Graur M, Gribovschi M, Mihai B, Mihalache L, Mihalcea M, Mindrescu N, Morosanu M, Morosoanu A, Mota M, Moza A, Nafornita V, Natea N, Nicodim S, Nita C, Onaca A, Onaca M, Pop C, Pop L, Popa A, Popescu A, Pruna L, Roman G, Rosu M, Sima A, Sipciu D, Sitterli-natea CN, Szilagyi I, Tapurica M, Tase A, Tutescu A, Vanghelie L, Verde I, Vlad A, Zarnescu M, Akhmetov R, Allenova I, Avdeeva I, Baturina O, Biserova I, Bokovin N, Bondar I, Burova N, Chufeneva G, Chumachek E, Demidova M, Demin A, Drobysheva V, Egorova I, Esenyan L, Gelig E, Gilyarevsky S, Golshmid M, Goncharov A, Gorbunova A, Gordeev I, Gorelysheva V, Goryunova T, Grebenshchikova I, Ilchenko R, Ivannikova M, Karabalieva S, Karpeeva J, Khaykina E, Kobalava Z, Kononenko I, Korolik O, Korshunova A, Kostenko V, Krasnopevtseva I, Krylova L, Kulkova P, Kuzmina I, Ledyaeva A, Levashov S, Lokhovinina N, Lvov V, Martirosyan N, Nedogoda S, Nilk R, Osmolovskaya Y, Panov A, Paramonova O, Pavlova E, Pekareva E, Petunina N, Ponamareva S, Reshedko G, Salasyuk A, Sepkhanyan M, Serebrov A, Shabelnikova O, Skvortsov A, Smirnova O, Spiridonova O, Strogova S, Taratukhin E, Tereschenko S, Trukhina L, Tsarkova O, Tsoma V, Tumarov F, Tyan N, Tyurina T, Villevalde S, Yankovaya E, Zarutskaya L, Zenkova E, Badat A, Bester F, Blignaut S, Blom D, Booysen S, Boyd W, Brice B, Brown S, Burgess L, Cawood R, Coetzee K, Conradie H, Cronje T, de Jong D, Ellis G, Emanuel S, Engelbrecht I, Foulkes S, Fourie D, Gibson G, Govender T, Hansa S, Hemus AC, Hendricks F, Heradien M, Holmgren C, Hoosain Z, Horak E, Howard J, Immink I, Janari E, Jivan D, Klusmann K, Labuschagne W, Lai Y, Latiff G, Lombaard J, Lottering H, Meeding R, Middlemost S, Mitha H, Mitha I, Mkhwanazi S, Moodley R, Murray A, Musungaie D, Osman Y, Peacey K, Pillay-ramaya L, Pretorius C, Prozesky H, Sarvan M, Scholtz E, Sebesteny A, Skinner B, Skriker M, Smit M, Stapelberg A, Swanepoel N, Urbach D, van Aswegen D, van Zyl F, Van Zyl L, Venter E, Wadvalla S, Wing J, Wolmarans K, Abreu C, Aguilà P, Aguilera E, Alonso N, Alvarez C, Cajas P, Castro JC, Codinachs R, Contreras J, Coves MJ, Fajardo C, Ferrer JC, Font N, Garcia M, Gil MA, Gomez F, Gomez LA, Gonzalbez J, Griera JL, Masmiquel L, Mauricio D, Narejos Perez S, Nicolau JA, Noheda Contreras O, Olivan J, Olivares J, Ortega E, Pellitero S, Pertusa S, Rius F, Rodriguez I, Sánchez-juan C, Santos D, Soldevila B, Subias D, Terns M, Trescoli C, Vilaplana J, Villanueva A, Albo J, Antus K, Axelsson M, Bergström L, Binsell-gerdin E, Boman K, Botond F, Dotevall A, Graipe A, Jarnet C, Kaminska J, Kempe A, Korhonen M, Linderfalk C, Liu B, Ljungstroem K, Ljungström K, Malmqvist L, Mellbin L, Mooe T, Nicol P, Norrby A, Ohlsson A, Rosengren A, Saaf J, Salmonsson S, Strandberg O, Svensson K, Tengmark B, Tsatsaris G, Ulvenstam A, Vasko P, Chang C, Chang H, Chen J, Chen T, Chung M, Fu C, Hsia T, Hua S, Kuo M, Lee C, Lee I, Liang K, Lin SY, Lu C, Ma W, Pei D, Shen F, Su C, Su S, Tai T, Tsai W, Tsai Y, Tung S, Wang J, Yu H, Al-qaissi A, Arutchelvam V, Atkin S, Au S, Aye MM, Bain S, Bejnariu C, Bell P, Bhatnagar D, Bilous R, Black N, Brennan U, Brett B, Bujanova J, Chow E, Collier A, Combe A, Courtney C, Courtney H, Crothers J, Eavis P, Elliott J, Febbraro S, Finlayson J, Gandhi R, Gillings S, Hamling J, Harper R, Harris T, Hassan K, Heller S, Jane A, Javed Z, Johnson T, Jones S, Kennedy A, Kerr D, Kilgallon B, Konya J, Lindsay J, Lomova-williams L, Looker H, Macfarlane D, Macrury S, Malik I, Mccrimmon R, Mckeith D, Mcknight J, Mishra B, Mukhtar R, Mulligan C, O'kane M, Olateju T, Orpen I, Richardson T, Rooney D, Ross SB, Sathyapalan T, Siddaramaiah N, Sit LE, Stephens J, Turtle F, Wakil A, Walkinshaw E, Ali A, Anderson R, Arakaki R, Aref O, Ariani MK, Arkin D, Banarer S, Barchini G, Bhan A, Branch K, Brautigam D, Brietzke S, Brinas M, Brito Y, Carter C, Casagni K, Casula S, Chakko S, Charatz S, Childress D, Chow L, Chustecka M, Clarke S, Cohen L, Collins B, Colon Vega G, Comulada-rivera A, Cortes-maisonet G, Davis M, de Souza J, Desouza C, Dinnan M, Duffy-hidalgo B, Dunn B, Dunn J, Elman M, Felicetta J, Finkelstein S, Fitz-patrick D, Florez H, Forker A, Fowler W, Fredrickson S, Freedman Z, Gainey Narron B, Gainey-ferree K, Gardner M, Gastelum C, Giddings S, Gillespie E, Gimness MP, Goldstein G, Gomes M, Gomez N, Gorman T, Goswami K, Graves A, Hacking S, Hall C, Hanson L, Harman S, Heber D, Henry R, Hiner J, Hirsch I, Hollander P, Hooker T, Horowitz B, Hoste L, Huang L, Huynh M, Hyman D, Idriss S, Iranmanesh A, Karounos D, Kashyap M, Katz L, Kaye W, Khaiton Y, Khardori R, Kitchen T, Klein A, Knffem W, Kosiborod M, Kreglinger N, Kruger D, Kumar A, Laboy I, Larrabee P, Larrick L, Lawson D, Ledet M, Lenhard J, Levy J, Li G, Li Z, Lieb D, Limcolioc A, Lions-patterson J, Lorber D, Lorch D, Lorrello M, Lu P, Lucas KJ, Ma S, Macadams M, Magee M, Magno A, Mahakala AR, Marks J, Mccall A, Mcclanahan W, Mcclary C, Melendez L, Melish J, Michaud D, Miller C, Miller N, Mora P, Moten M, Mudaliar S, Myrick G, Narayan P, Nassif M, Neri K, Newton T, Niblack P, Nicol P, Nyenwe E, Odugbesan AO, Okorocha Y, Ortiz Carrasquillo R, Osei K, Palermo C, Patel H, Patel K, Pau C, Perley M, Plevin S, Plummer E, Powell R, Qintar M, Rawls R, Reyes-castano J, Reynolds L, Richards R, Rosenstock J, Rowe C, Saleh J, Sam S, Sanchez A, Sander D, Sanderson B, Savin V, Seaquist E, Shah J, Shi S, Shivaswamy V, Shlotzhauer T, Shore D, Skukowski B, Soe K, Solheim V, Soufer J, Steinberg H, Steinsapir J, Tarkington P, Thayer D, Thomson S, Thrasher J, Tibaldi J, Tjaden J, Tores O, Trence D, Trikudanathan S, Ullal J, Uwaifo G, Vo A, Vu K, Walia D, Weiland K, Whitehouse F, Wiegmann T, Wyne K, Wynne A, Yuen K, Zaretzky J, Zebrack J, Zieve F, Zigrang W. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet 2019;394:121-30. [DOI: 10.1016/s0140-6736(19)31149-3] [Cited by in Crossref: 650] [Cited by in F6Publishing: 271] [Article Influence: 216.7] [Reference Citation Analysis]
160 Scheen AJ. Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond. Ann Transl Med 2019;7:S132. [PMID: 31576339 DOI: 10.21037/atm.2019.05.82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Matthews DR, Paldánius PM, Stumvoll M, Han J, Bader G, Chiang Y, Proot P, Del Prato S. A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Diabetes Obes Metab 2019;21:2240-7. [PMID: 31144427 DOI: 10.1111/dom.13800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
162 Mishriky BM, Powell JR, Wittwer JA, Chu JX, Sewell KA, Wu Q, Cummings DM. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:2274-83. [PMID: 31168889 DOI: 10.1111/dom.13805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
163 Tsai SF, Chen CH. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. Int J Mol Sci. 2019;20. [PMID: 31261624 DOI: 10.3390/ijms20133152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
164 Vargas-Uricoechea H, Frias JP. Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. Diabetes Metab Syndr 2019;13:1975-89. [PMID: 31235124 DOI: 10.1016/j.dsx.2019.04.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Ramzan S, Timmins P, Hasan SS, Babar ZU. Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000-2018. Prim Care Diabetes 2019;13:409-21. [PMID: 31213359 DOI: 10.1016/j.pcd.2019.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
166 Kant R, Munir KM, Kaur A, Verma V. Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. World J Diabetes 2019; 10(6): 324-332 [PMID: 31231455 DOI: 10.4239/wjd.v10.i6.324] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
167 Rodriguez-Gutierrez R, McCoy RG. Measuring What Matters in Diabetes. JAMA 2019;321:1865-6. [PMID: 30985865 DOI: 10.1001/jama.2019.4310] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
168 Scheen AJ. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view. Diabetes Res Clin Pract 2020;159:107726. [PMID: 31108136 DOI: 10.1016/j.diabres.2019.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
169 Niezen S, Diaz Del Castillo H, Mendez Castaner LA, Fornoni A. Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinol Diabetes Metab 2019;2:e00072. [PMID: 31294086 DOI: 10.1002/edm2.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Hernando VU, Pablo FJ. Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. Diabetes Metab Syndr 2019;13:2126-41. [PMID: 31235147 DOI: 10.1016/j.dsx.2019.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
171 Darsalia V, Johansen OE, Lietzau G, Nyström T, Klein T, Patrone C. Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. Front Neurol 2019;10:493. [PMID: 31139140 DOI: 10.3389/fneur.2019.00493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
172 . Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. JAMA 2019;321:1720-1. [PMID: 31063571 DOI: 10.1001/jama.2019.2702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
173 Hupfeld C, Mudaliar S. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. Diabetes Obes Metab 2019;21:1780-9. [PMID: 30957945 DOI: 10.1111/dom.13740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
174 Hanssen NM, Jandeleit-Dahm KA. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? Diab Vasc Dis Res 2019;16:303-9. [PMID: 31018682 DOI: 10.1177/1479164119842339] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
175 Clodi M, Saely CH, Hoppichler F, Resl M, Steinwender C, Stingl H, Wascher TC, Winhofer-Stöckl Y, Sourij H. [Diabetes mellitus, coronary artery disease und heart disease (Update 2019)]. Wien Klin Wochenschr 2019;131:169-73. [PMID: 30980152 DOI: 10.1007/s00508-019-1488-3] [Reference Citation Analysis]
176 Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes & Endocrinology 2019;7:313-24. [DOI: 10.1016/s2213-8587(18)30154-2] [Cited by in Crossref: 368] [Cited by in F6Publishing: 229] [Article Influence: 122.7] [Reference Citation Analysis]
177 Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461-2498. [PMID: 30288571 DOI: 10.1007/s00125-018-4729-5] [Cited by in Crossref: 562] [Cited by in F6Publishing: 571] [Article Influence: 187.3] [Reference Citation Analysis]
178 Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. J Intern Med 2019;286:16-31. [PMID: 30888088 DOI: 10.1111/joim.12890] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
179 McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. Diabetes Obes Metab 2019;21:1073-8. [PMID: 30690856 DOI: 10.1111/dom.13645] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
180 Kostev K, Gölz S, Scholz BM, Kaiser M, Pscherer S. Time to Insulin Initiation in Type 2 Diabetes Patients in 2010/2011 and 2016/2017 in Germany. J Diabetes Sci Technol 2019;13:1129-34. [PMID: 30862186 DOI: 10.1177/1932296819835196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
181 Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab 2019;21:1299-304. [PMID: 30714309 DOI: 10.1111/dom.13649] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
182 Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2019;18:30. [PMID: 30857522 DOI: 10.1186/s12933-019-0822-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
183 Vetrone LM, Zaccardi F, Webb DR, Seidu S, Gholap NN, Pitocco D, Davies MJ, Khunti K. Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis. Acta Diabetol 2019;56:331-9. [PMID: 30456728 DOI: 10.1007/s00592-018-1253-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
184 Bailey CJ. FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later. Diabetes Obes Metab 2019;21:1079-80. [PMID: 30762280 DOI: 10.1111/dom.13669] [Reference Citation Analysis]
185 Fritzen K, Schnell O. PDM-ProValue meets cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2019;18:10. [PMID: 30691463 DOI: 10.1186/s12933-019-0815-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Santos Cavaiola T, Kiriakov Y, Reid T. Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. Clin Ther 2019;41:352-67. [PMID: 30655008 DOI: 10.1016/j.clinthera.2018.11.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
187 Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. J Med Econ 2019;22:280-7. [PMID: 30575426 DOI: 10.1080/13696998.2018.1562817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
188 Bajaj HS, Zinman B. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. Physiology (Bethesda) 2018;33:197-210. [PMID: 29638185 DOI: 10.1152/physiol.00004.2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Fourny N, Lan C, Sérée E, Bernard M, Desrois M. Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart. Nutrients 2019;11:E105. [PMID: 30621358 DOI: 10.3390/nu11010105] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
190 Gerstein HC, Mcmurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. The Lancet 2019;393:210-1. [DOI: 10.1016/s0140-6736(18)32840-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 17.7] [Reference Citation Analysis]
191 Doupis J; Diabetes Division and Clinical Research Center, Iatriko Paleou Falirou Medical Center, Paleo Faliro, Greece; Internal Medicine, Diabetes Department, NS Naval Hospital, Athens, Greece. Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial. US Endocrinology 2019;15:65. [DOI: 10.17925/use.2019.15.2.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
192 Ashraf H, Ahmad J. Cardiovascular outcome trials in type 2 diabetes: A critical analysis. Diabetes Metab Syndr 2019;13:300-5. [PMID: 30641716 DOI: 10.1016/j.dsx.2018.09.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Witham MD. Bridging the gap between the laboratory and the clinic for patients with sarcopenia. Biogerontology 2019;20:241-8. [PMID: 30591980 DOI: 10.1007/s10522-018-09793-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
194 Armstrong EJ, Waldo SW, Valle JA. The Heart and Vascular Team: Time for Endocrinologists to Join the Club? J Am Coll Cardiol 2018;72:3285-6. [PMID: 30573031 DOI: 10.1016/j.jacc.2018.10.032] [Reference Citation Analysis]
195 American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S103-23. [PMID: 30559236 DOI: 10.2337/dc19-S010] [Cited by in Crossref: 304] [Cited by in F6Publishing: 269] [Article Influence: 76.0] [Reference Citation Analysis]
196 Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol 2018;17:157. [PMID: 30545359 DOI: 10.1186/s12933-018-0800-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 12.5] [Reference Citation Analysis]
197 Guerci B, Trautmann ME, Lin T, Hardy E, Mudaliar SRD. Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study. Diabetes Obes Metab 2019;21:1049-53. [PMID: 30520252 DOI: 10.1111/dom.13606] [Reference Citation Analysis]
198 Cheng JWM, Colucci VJ, Kalus JS, Spinler SA. Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent? Ann Pharmacother. 2019;53:510-522. [PMID: 30516068 DOI: 10.1177/1060028018816466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Sinclair AJ, Abdelhafiz AH, Forbes A, Munshi M. Evidence-based diabetes care for older people with Type 2 diabetes: a critical review. Diabet Med. 2018;. [PMID: 30411402 DOI: 10.1111/dme.13859] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
200 Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;72:3200-23. [PMID: 30497881 DOI: 10.1016/j.jacc.2018.09.020] [Cited by in Crossref: 170] [Cited by in F6Publishing: 182] [Article Influence: 42.5] [Reference Citation Analysis]
201 Dhindsa DS, Sandesara PB, Shapiro MD. The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies. Front Cardiovasc Med 2018;5:160. [PMID: 30555833 DOI: 10.3389/fcvm.2018.00160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
202 Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab 2019;21:499-508. [PMID: 30284349 DOI: 10.1111/dom.13553] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 11.5] [Reference Citation Analysis]
203 Scheen AJ. Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin? Diabetes Res Clin Pract 2019;147:169-71. [PMID: 30391502 DOI: 10.1016/j.diabres.2018.10.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
204 Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 2018;19:1903-14. [PMID: 30299993 DOI: 10.1080/14656566.2018.1531126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
205 Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-2701. [PMID: 30291106 DOI: 10.2337/dci18-0033] [Cited by in Crossref: 1397] [Cited by in F6Publishing: 1197] [Article Influence: 349.3] [Reference Citation Analysis]
206 Khunti K, Seidu S, Davies MJ. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes? Diabetes Obes Metab 2019;21:207-9. [DOI: 10.1111/dom.13518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
207 Vargas-Uricoechea H, Cáceres-Acosta MF. Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature. Clin Investig Arterioscler 2019;31:31-47. [PMID: 30274771 DOI: 10.1016/j.arteri.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Kjaer LK, Oellgaard J, Henriksen T, Gaede P, Pedersen O, Poulsen HE. Indicator of RNA oxidation in urine for the prediction of mortality in patients with type 2 diabetes and microalbuminuria: A post-hoc analysis of the Steno-2 trial. Free Radic Biol Med 2018;129:247-55. [PMID: 30244028 DOI: 10.1016/j.freeradbiomed.2018.09.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
209 Ferrannini G, Rydén L. Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data. Clinical Science 2018;132:2003-12. [DOI: 10.1042/cs20171374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
210 Bilal A, Pratley RE. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. Curr Diab Rep 2018;18. [DOI: 10.1007/s11892-018-1086-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
211 DeVore AD, Green JB. Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect? JACC Heart Fail 2018;6:831-2. [PMID: 30196074 DOI: 10.1016/j.jchf.2018.07.014] [Reference Citation Analysis]
212 Accili D. Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture. Diabetes 2018;67:1701-9. [PMID: 30135131 DOI: 10.2337/dbi18-0025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
213 Muskiet MHA, van Baar MJB, Scholtes RA, van Raalte DH. Renal outcomes in CVOTs: keep calm and carry on. The Lancet Diabetes & Endocrinology 2018;6:674-6. [DOI: 10.1016/s2213-8587(18)30195-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab 2018;20:2711-23. [PMID: 30003655 DOI: 10.1111/dom.13468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
215 Frampton JE. Empagliflozin: A Review in Type 2 Diabetes. Drugs 2018;78:1037-48. [DOI: 10.1007/s40265-018-0937-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
216 Scheen AJ. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. Diabetes Metab 2018;44:386-92. [PMID: 30126735 DOI: 10.1016/j.diabet.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
217 Holman RR. What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us? J Diabetes 2018;10:683-5. [PMID: 29774661 DOI: 10.1111/1753-0407.12770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
218 Maddaloni E, Buzzetti R. Why only macro and not micro in type 2 diabetes? Time to change the goals of clinical trials in diabetes. Diabetes Metab Res Rev 2018;34:e3012. [DOI: 10.1002/dmrr.3012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
219 De Block C. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination. The Lancet Diabetes & Endocrinology 2018;6:349-52. [DOI: 10.1016/s2213-8587(18)30031-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
220 Reynolds L, Genuth SM. The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress. Diabetes Care 2018;41:241-9. [PMID: 29358468 DOI: 10.2337/dci17-0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]